Clopidogrel Bisulfate
NDC Package 62034-015-90

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Clopidogrel Bisulfate is •For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel bisulate has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.•For patients with ST-elevation myocardial infarction (STEMI), clopidogdrel bisulfate has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. Marketed by Blenheim Pharmacal, Inc., this product is identified by NDC 62034-015 and is authorized under FDA application ANDA076274.

Identification & Billing

NDC Package Code
62034-015-90
Package Description
90 TABLET, FILM COATED in 1 BOTTLE
Product Code
62034-015
11-Digit Billing Format
62034001590
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Clopidogrel Bisulfate
Dosage Form
-
Usage Information
•For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel bisulate has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.•For patients with ST-elevation myocardial infarction (STEMI), clopidogdrel bisulfate has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.The optimal duration of clopidogrel bisulfate therapy in ACS is unknown.

Regulatory & Marketing

Labeler Name
Blenheim Pharmacal, Inc.
FDA Application #
ANDA076274
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-14-2014
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (62034-015). Click a package code to view its specific billing and regulatory data.

62034-015-01
100 TABLET, FILM COATED in 1 BOTTLE
62034-015-30
30 TABLET, FILM COATED in 1 BOTTLE
62034-015-77
10 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62034-015-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Clopidogrel Bisulfate, labeled by Blenheim Pharmacal, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Blenheim Pharmacal, Inc. on February 14, 2014. The current certification is valid through December 31, 2017.

How is this Blenheim Pharmacal, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62034001590. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62034-015-90
11-Digit CMS (5-4-2)
62034-0015-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.